American Society for Mass Spectrometry

Photonis Expands Market-Leading Mass Spectrometry Detection Technology

Retrieved on: 
Tuesday, May 23, 2023

Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.

Key Points: 
  • Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.
  • At this occasion, Photonis, the leaders in Time-of-Flight (TOF) detection technologies, will showcase their latest advancements in TOF detection with additions to their existing detector platforms - the APTOF and BPTOF Series.
  • Ulrich Laupper, President and General Manager of Photonis' Ultimate Detection Business Unit: "We are excited to introduce the next generation of Time-of-Flight detection technology at this year's ASMS Conference.
  • The APTOF A300 and BPTOF B380 provide mass spectrometry instrument manufacturers an unmatched cost-of-ownership value proposition.

Quantum-Si Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 7, 2023

Operating expenses were $27.0 million in the second quarter of 2023, compared to $30.2 million in the second quarter of 2022.

Key Points: 
  • Operating expenses were $27.0 million in the second quarter of 2023, compared to $30.2 million in the second quarter of 2022.
  • Net loss was $25.6 million in the second quarter of 2023, compared to a net loss of $32.4 million in the second quarter of 2022.
  • Adjusted EBITDA was negative $22.9 million in the second quarter of 2023, compared to negative $25.8 million in the second quarter of 2022.
  • Quantum-Si will host a conference call to discuss its second quarter 2023 financial results on Monday, August 7, 2023, at 8:30 AM Eastern Time.

Biognosys Unveils Innovative Workflow for Deep and Reproducible Plasma Proteomics, Enabling Breakthroughs in Molecular Diagnostics and Drug Development

Retrieved on: 
Wednesday, June 7, 2023

By implementing fully automated sample processing relying on bead-based parallel depletion methodology, Biognosys has achieved a remarkable 35% reduction in processing time and an 85% decrease in hands-on time.

Key Points: 
  • By implementing fully automated sample processing relying on bead-based parallel depletion methodology, Biognosys has achieved a remarkable 35% reduction in processing time and an 85% decrease in hands-on time.
  • Furthermore, the utilization of a bead-based plasma depletion workflow has led to a significant 22% increase in protein identifications, enabling robust and reproducible quantification of nearly 4,000 proteins in human plasma samples.
  • “Blood plasma offers a unique window into the human body,” added Kristina Beeler, Ph.D., Chief Product Development and Marketing Officer at Biognosys.
  • Biognosys is making this advanced workflow available to their global customer base, comprising over 800 biopharma and academic customers, through their proprietary TrueDiscovery™ platform.

Waters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging

Retrieved on: 
Monday, June 5, 2023

HOUSTON, June 5, 2023 /PRNewswire/ -- American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today announced new updates to its SELECT SERIES™ MRT System that increases its specificity and utility for UPLC-MS/MS metabolomics and drug discovery applications and for mass spectrometry imaging experiments. The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.

Key Points: 
  • New resolution enhancement mode (REM) for Waters' multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity and higher sample throughput for metabolomics UPLC™-MS/MS and MS imaging studies.
  • The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.
  • It is compatible with numerous MS imaging sources including DESI and MALDI, and generates crystal-clear, high-resolution images without compromising mass spectral resolution or accuracy.
  • The new resolution enhancement mode is available as an optional upgrade to currently installed and new SELECT SERIES MRT Systems.

Waters Takes Targeted, Quantitative Imaging to the Next Level with New DESI Source for the Xevo TQ Absolute System

Retrieved on: 
Monday, June 5, 2023

HOUSTON, June 5, 2023 /PRNewswire/ -- American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today launched the industry's first targeted imaging mass spectrometer based on its Xevo™ TQ Absolute tandem quadrupole mass spectrometer, the most sensitive and compact mass spectrometer in its class. The new instrument combines the Waters™ DESI XS source with the Xevo TQ Absolute system and is five times more sensitive and five times faster than discovery-based imaging systems at precisely determining whether a particular small molecule drug product – and how much of it - reaches its intended target, such as a brain, liver, or lung, in a test subject.

Key Points: 
  • Waters combines the enhanced desorption electrospray ionization (DESI) source with the Xevo TQ Absolute tandem quadrupole mass spectrometer to enable faster and more sensitive targeted pre-clinical MS imaging experiments.
  • Waters adds DESI XS source to its Xevo TQ Absolute mass spectrometer for fast and sensitive targeted MS imaging.
  • "Customers have successfully applied the Xevo TQ Absolute system to solve a host of problems including PFAS testing at parts-per-quadrillion levels," said Jon Pratt, Senior Vice President, Waters Division.
  • "The DESI XS source features a high-performance sprayer and that makes the DESI source robust so we can work much more efficiently," said Dr. Akakpo.

Olaris, Inc. debuts novel global QqQ LC mass spectrometry panel for clinical metabolomics applications at the American Society for Mass Spectrometry 2023 Meeting

Retrieved on: 
Monday, June 5, 2023

FRAMINGHAM, Mass., June 5, 2023 /PRNewswire-PRWeb/ -- Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company's research on developing a triple-quadrupole (QqQ) mass spectrometry (MS) platform for clinical metabolomics applications has been selected for a poster presentation on June 5th at the upcoming American Society for Mass Spectrometry (ASMS) 2023 Annual Meeting, to be held June 4th-8th in Houston, TX.

Key Points: 
  • Combined with their existing high-field multidimensional NMR technology, the new Olaris QqQ panel enables global, quantitative reproducible measurements of hundreds of metabolites for clinical and biopharmaceutical research.
  • "The new QqQ technology will expand our ability to detect clinically impactful changes in metabolites.
  • Yet due to challenges with analytical measurements and reproducibility concerns, metabolomics has yet to reach its full potential in diagnostic and drug development.
  • For more information on the ASMS meeting or to view the Olaris presentation during the conference, visit http://www.asms.org .

Thermo Fisher Scientific Showcases Solutions for Accelerating Biological Discovery

Retrieved on: 
Monday, June 5, 2023

Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery.

Key Points: 
  • Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery.
  • A seamless connection with the Thermo Scientific Ardia platform amplifies productivity and unlocks deeper insights into biotherapeutic characterization leading to safer biotherapies and vaccines.
  • New Thermo Scientific™ TraceFinder™ 5.2 SP1 software delivers innovative and flexible solutions for high throughput library screening and quantitation laboratories.
  • For more information on the Thermo Fisher solutions exhibited at ASMS 2023, please visit www.thermofisher.com/ASMS .

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Retrieved on: 
Monday, June 5, 2023

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years.
  • Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230605005016/en/
    The Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer offers accurate and precise quantitation in proteomics laboratories with faster throughput, deeper coverage and higher sensitivity than the current state-of-the-art.
  • “The Orbitrap Astral mass spectrometer is a true gamechanger, offering an unrivaled combination of sensitivity, dynamic range and speed that doesn’t compromise accurate and precise quantitation.

MOBILion to Showcase Innovations in Separation Science - New Capabilities and Application Workflows at ASMS 2023

Retrieved on: 
Thursday, June 1, 2023

MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.

Key Points: 
  • MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.
  • In six seminar presentations, industry collaborators will present data demonstrating the unique ability to solve their analytical challenges with high-resolution ion mobility (HRIM-MS).
  • ASMS provides the perfect venue to share our latest advancements and foster collaborations that will drive innovation forward."
  • To obtain further details regarding MOBILion Systems' presence at ASMS 2023 and to register for the events, please visit: https://info.mobilionsystems.com/asms2023 .

Biognosys Launches Spectronaut 18 and Presents Advances in Proteomics Depth, Sensitivity, and Scalability at the ASMS 2023 Annual Conference

Retrieved on: 
Wednesday, May 31, 2023

Biognosys’ scientific presence includes a breakfast seminar introducing Spectronaut 18, along with three oral presentations and nine posters.

Key Points: 
  • Biognosys’ scientific presence includes a breakfast seminar introducing Spectronaut 18, along with three oral presentations and nine posters.
  • “Our continuous commitment to innovation in mass spectrometry-based proteomics is once again emphasized by our significant contribution to the ASMS scientific program,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
  • A major launch arising from the strategic partnership is the combination of Biognosys’ iRT kit together with the Bruker ProteoScape™ product.
  • Biognosys will launch the latest version of Spectronaut during their Monday, June 5, breakfast seminar “Spectronaut 18: Limitless Throughput.